About the company
Board of directors
Dementia & Alzheimer's disease
Dementia in Down syndrome
The dementia market
The Science behind Pharmasum
Protein kinase DYRK1A
DYRK1A - Role in different diseases
Proprietary inhibitors of DYRK1A
SBDD – Structure-Based Drug Design
"Pharmasum is gearing up to enter clinical studies in Down syndrome.
We are trying to dramatically improve the lives of individuals with Down syndrome, by improving cognition and possibly slowing down Alzheimer's pathology."
Click here to view publication